Skip to main content

Table 1 Baseline demographic and clinical characteristics

From: Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors

Characteristic CRC Non-CRC Overall study population
(N = 103)
 ≥ 2 Prior therapies (N = 41) 1 Prior therapy (N = 24) Total
(N = 65)
GC
(N = 18)
Other solid tumors
(N = 20)
Total
(N = 38)
Age (years)        
Median 48.0 50.5 49.0 61.0 56.0 58.5 53.0
Range 25–77 22–76 22–77 34–72 36–75 34–75 22–77
Sex, n (%)        
Male 30 (73) 13 (54) 43 (66) 14 (78) 8 (40) 22 (58) 65 (63)
Female 11 (27) 11 (46) 22 (34) 4 (22) 12 (60) 16 (42) 38 (37)
Ethnicity, n (%)        
Han Chinese 39 (95) 21 (87.5) 60 (92) 18 (100) 20 (100) 38 (100) 98 (95)
Other 2 (5) 3 (12.5) 5 (8) 0 0 0 5 (5)
ECOG PS, n (%)        
0 10 (24) 7 (29) 17 (26) 3 (17) 7 (35) 10 (26) 27 (26)
1 31 (76) 17 (71) 48 (74) 15 (83) 13 (65) 28 (74) 76 (74)
Cancer diagnosis, n (%)        
Colorectal cancer 41 24 65 65 (63)
Gastric/gastroesophageal junction cancer 18 18 18 (17)
Other solid tumors 20 20 20 (19)
Endometrial cancer 6 6 6 (6)
Hepatocellular cancer 2 2 2 (2)
Hepatocholangiocarcinoma 2 2 2 (2)
Bladder cancer 1 1 1 (1)
Cervical cancer 1 1 1 (1)
Cholangiocarcinoma 1 1 1 (1)
Esophageal cancer 1 1 1 (1)
Non-small cell lung cancer 1 1 1 (1)
Osteosarcoma 1 1 1 (1)
Prostate cancer 1 1 1 (1)
Renal pelvic carcinoma 1 1 1 (1)
Urothelial carcinoma 1 1 1 (1)
Uterine sarcoma 1 1 1 (1)
Number of prior systemic treatments        
Median 3 2 3 2 2 2 2
Range 1–7 1–4 1–7 1–4 1–5 1–5 1–7
  1. CRC with ≥ 2 prior therapies included patients previously treated with a fluoropyrimidine-, oxaliplatin-, and irinotecan-containing regimen
  2. CRC with 1 prior therapy included patients previously treated with a fluoropyrimidine- and oxaliplatin- or fluoropyrimidine- and irinotecan-containing regimen
  3. CRC, colorectal cancer; ECOG, Eastern Cooperative Oncology Group; GC, gastric cancer; PS, performance status